APA (7th ed.) Citation

Yamamoto, Y., Wada, O., Yanagisawa, J., Kato, S., & Kitazato, K. (2002). A novel antiestrogen, TAS-108 (SR16234) shows full antagonistic activity to ER alpha and beta with a unique mechanism. European Journal of Cancer, 38, S96. https://doi.org/10.1016/s0959-8049(02)80303-3

Chicago Style (17th ed.) Citation

Yamamoto, Y., O. Wada, J. Yanagisawa, S. Kato, and K. Kitazato. "A Novel Antiestrogen, TAS-108 (SR16234) Shows Full Antagonistic Activity to ER Alpha and Beta with a Unique Mechanism." European Journal of Cancer 38 (2002): S96. https://doi.org/10.1016/s0959-8049(02)80303-3.

MLA (9th ed.) Citation

Yamamoto, Y., et al. "A Novel Antiestrogen, TAS-108 (SR16234) Shows Full Antagonistic Activity to ER Alpha and Beta with a Unique Mechanism." European Journal of Cancer, vol. 38, 2002, p. S96, https://doi.org/10.1016/s0959-8049(02)80303-3.